Prince A M, Szmuness W, Michon J, Demaille J, Diebolt G, Linhard J, Quenum C, Sankale M
Int J Cancer. 1975 Sep 15;16(3):376-83. doi: 10.1002/ijc.2910160304.
A case/control study has been carried out to determine by radioimmunoassay and passive hemagglutination techniques the prevalence of hepatitis B surface antigen (HBsAg) and antibody (anti-HBs) in patients with primary liver cancer (PLC) and age/sex-matched hospital controls with cancers of other sites (OCC) and similarly matched controls without cancer (NCC). HBsAg was found in 61.2% of 165 cases of PLC as compared to 11.7% of 328 NCC. The frequency of HBsAg in PLC patients was significantly higher (72.2%) in those with detectable alpha fetoprotein as compared to those without (40.3%). There was no difference in the frequency of HBsAg in PLC patients with and without accompanying cirrhosis. No significant difference in potential hepatitis exposure history was found in the three study groups.
开展了一项病例对照研究,通过放射免疫测定法和被动血凝技术,确定原发性肝癌(PLC)患者以及年龄/性别匹配的其他部位癌症(OCC)医院对照患者和无癌症的类似匹配对照患者(NCC)中乙肝表面抗原(HBsAg)和抗体(抗-HBs)的流行情况。在165例PLC患者中,61.2%发现有HBsAg,而328例NCC中这一比例为11.7%。与未检测到甲胎蛋白的PLC患者相比,检测到甲胎蛋白的PLC患者中HBsAg的频率显著更高(72.2%)。伴有和不伴有肝硬化的PLC患者中HBsAg的频率没有差异。三个研究组在潜在肝炎暴露史方面未发现显著差异。